胞内抗体和胞内因子技术与疾病的分子治疗
作者：傅刘鹏;马伟峰;张彦东;蔡绍晖;
Author：
收稿日期： 年卷（期）页码：2009,24(01):-99-101
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：胞内抗体;胞内因子;分子治疗
Key words：
基金项目：国家自然科学基金资助项目(批准号:30572209)
中文摘要
胞内抗体和胞内因子技术是一种新颖的基因治疗策略,也是用于表型敲除研究的又一有力工具。胞内抗体/因子通过基因重组技术在细胞内表达并被定位于特定的亚细胞器中,能够特异性地结合细胞内靶分子,进而影响靶分子的加工或分泌过程及其生物学效应,已在人艾滋病、恶性肿瘤、移植排斥和神经变性等疾病的分子治疗领域彰显出潜在的应用前景。
参考文献
[1]Wheeler YRY,Chen SY,Sane DC.Intrabody and intrakine strate-gies for molecular therapy[J].Molecular Therapy,2003,8(3):355-366.
[2]张颖,白雪帆,李靖,等.淋巴细胞HIV-1辅受体表型剔除阻断病毒感染的研究[J].中华微生物学和免疫学杂志,2004,24(1):72-75.
[3]Cordelier P,Kulkowsky JW,Ko C,et al.Protecting from R5-tropic HIV:individual and combined effectiveness of a hammer-head ribozyme and a single-chain Fv antibody that targets CCR5[J].Gene Therapy,2004,11(22):1627-1637.
[4]Goncalves J,Silva F,Freitas-Vieira A,et al.Functional neutral-ization of HIV-1Vif protein by intracellular immunization inhib-its reverse transcription and viral replication[J].J Biolog Chem,2002,277(35):32036-32045.
[5]Mhashilkar AM,LaVecchio J,Eberhardt B,et al.Inhibition of hu-man immunodeficiency virus type1replication in vitro in acutely and persistently infected human CD4(+)mononuclear cells ex-pressing murine and humanized anti-human immunodeficiency virus type1Tat single-chain variable fragment intrabodies[J].Human Gene Therapy,1999,10(9):1453-1467.
[6]Alvarez RD,Barnes MN,Gomez-Navarro J,et al.A cancer gene therapy approach utilizing an anti-erbB-2single-chain anti-body-encoding adenovirus(AD21):A phase I trial[J].Clin Can Res,2000,6(8):3081-3087.
[7]Wheeler YRY,Kute TE,Willingham MC,et al.Intrabody-based strategies for inhibition of vascular endothelial growth factor re-ceptor-2:effects on apoptosis,cell growth,and angiogenesis[J].Faseb J,2003,17(10):1733.
[8]Zeelenberg IS,L Ruuls-Van Stalle,Roos E.Retention of CX-CR4in the endoplasmic reticulum blocks dissemination of a T cell hybridoma[J].J Clin Invest,2001,108(2):269-277.
[9]Busch A,Marasco WA,Doebis C,et al.MHC class Imanipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies-a tool for decreased immunogenicity of allogeneic tissue and cell transplants[J].Methods,2004,34(2):240-249.
[10]Beyer F,Doebis C,Busch A,et al.Decline of surface MHC I by adenoviral gene transfer of anti-MHC I intrabodies in human en-dothelial cells-new perspectives for the generation of universal donor cells for tissue transplantation[J].J Gene Medicine,2004,6(6):616-623.
[11]Lecerf JM,Shirley TL,Zhu Q,et al.Human single-chain Fv in-trabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease[J].Proceedings of the National Academy of Sciences USA,2001,98(8):4764-4769.
[12]Paganetti P,Calanca V,Galli C,et al.Beta-site specific intra-bodies to decrease and prevent generation of Alzheimer's A beta peptide[J].J Cell Biology,2005,168(6):863-868.
[13]Lobato MN,TH Rabbitts.Intracellular antibodies and challenges facing their use as therapeutic agents[J].Trends in Mole Med,2003,9(9):390-396.
【关闭】
